View Item 

Show simple item record

Longitudinal Change in Quality of Life in Neurological Disorders Measures Over 3- Years in Patients with Early Parkinson’s Disease
dc.contributor.authorMarras, Connie
dc.contributor.authorMills, Kelly A.
dc.contributor.authorEberly, Shirley
dc.contributor.authorOakes, David
dc.contributor.authorChou, Kelvin L.
dc.contributor.authorHalverson, Matthew
dc.contributor.authorParashos, Sotirios A.
dc.contributor.authorTarolli, Christopher G.
dc.contributor.authorLai, Jin‐shei
dc.contributor.authorNowinsky, Cindy J.
dc.contributor.authorSuchowersky, Oksana
dc.contributor.authorFarbman, Eric S.
dc.contributor.authorShulman, Lisa M.
dc.contributor.authorSimuni, Tanya
dc.date.accessioned2021-09-08T14:35:49Z
dc.date.available2022-09-08 10:35:47en
dc.date.available2021-09-08T14:35:49Z
dc.date.issued2021-08
dc.identifier.citationMarras, Connie; Mills, Kelly A.; Eberly, Shirley; Oakes, David; Chou, Kelvin L.; Halverson, Matthew; Parashos, Sotirios A.; Tarolli, Christopher G.; Lai, Jin‐shei ; Nowinsky, Cindy J.; Suchowersky, Oksana; Farbman, Eric S.; Shulman, Lisa M.; Simuni, Tanya (2021). "Longitudinal Change in Quality of Life in Neurological Disorders Measures Over 3- Years in Patients with Early Parkinson’s Disease." Movement Disorders 36(8): 1979-1983.
dc.identifier.issn0885-3185
dc.identifier.issn1531-8257
dc.identifier.urihttps://hdl.handle.net/2027.42/169296
dc.description.abstractBackgroundThe Quality of Life in Neurological Disorders (Neuro- QoL) is a publicly available health- related quality- of- life measurement system.ObjectiveThe aim of this study was to evaluate the utility of Neuro- QoL item banks as outcome measures for clinical trials in Parkinson’s disease.MethodsAn analysis of Neuro- QoL responsiveness to change and construct validity was performed in a multicenter clinical trial cohort.ResultsAmong 310 participants over 3- years, changes in five of eight Neuro- QoL domains were significant (P <- 0.05) but very modest. The largest effect sizes were seen in the cognition and mobility domains (0.35- 0.39). The largest effect size for change over the year in which levodopa was initiated was - 0.19 for lower extremity function- mobility. For a similarly designed clinical trial, estimated sample size required to demonstrate a 50% reduction in worsening ranged from 420 to more than 1000 participants per group.ConclusionsMore sensitive tools will be required to serve as an outcome measure in early Parkinson’s disease. © 2021 International Parkinson and Movement Disorder Society
dc.publisherJohn Wiley & Sons, Inc.
dc.subject.otherquality of life
dc.subject.othermeasurement
dc.subject.otherParkinson’s disease
dc.subject.otherNeuro- QoL
dc.titleLongitudinal Change in Quality of Life in Neurological Disorders Measures Over 3- Years in Patients with Early Parkinson’s Disease
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/169296/1/mds28641.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/169296/2/mds28641_am.pdf
dc.identifier.doi10.1002/mds.28641
dc.identifier.sourceMovement Disorders
dc.identifier.citedreferenceUS Food and Drug Administration. Patient- Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. 2009. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-reported-outcome-measures-use-medical-product-development-support-labeling-claims
dc.identifier.citedreferenceCella D, Lai JS, Nowinski CJ, et al. Neuro- QOL: brief measures of health- related quality of life for clinical research in neurology. Neurology 2012; 78 ( 23 ): 1860 - 1867.
dc.identifier.citedreferenceNowinski CJ, Siderowf A, Simuni T, Wortman C, Moy C, Cella D. Neuro- QoL health- related quality of life measurement system: validation in Parkinson’s disease. Mov Disord 2016; 31 ( 5 ): 725 - 733.
dc.identifier.citedreferenceShulman LM, Armstrong M, Ellis T, et al. Disability rating scales in Parkinson’s disease: critique and recommendations. Mov Disord 2016; 31 ( 10 ): 1455 - 1465.
dc.identifier.citedreferenceMartinez- Martin P, Jeukens- Visser M, Lyons KE, et al. Health- related quality- of- life scales in Parkinson’s disease: critique and recommendations. Mov Disord 2011; 26 ( 13 ): 2371 - 2380.
dc.identifier.citedreferenceSprangers MA, Schwartz CE. Integrating response shift into health- related quality of life research: a theoretical model. Soc Sci Med 1999; 48 ( 11 ): 1507 - 1515.
dc.identifier.citedreferenceRegnault A, Boroojerdi B, Meunier J, Bani M, Morel T, Cano S. Does the MDS- UPDRS provide the precision to assess progression in early Parkinson’s disease? Learnings from the Parkinson’s progression marker initiative cohort. J Neurol 2019; 266 ( 8 ): 1927 - 1936.
dc.identifier.citedreferenceSimuni T, Siderowf A, Lasch S, et al. Longitudinal change of clinical and biological measures in early Parkinson’s disease: Parkinson’s progression markers initiative cohort. Mov Disord 2018; 33 ( 5 ): 771 - 782.
dc.identifier.citedreferenceShulman LM, Gruber- Baldini AL, Anderson KE, et al. The evolution of disability in Parkinson disease. Mov Disord 2008; 23 ( 6 ): 790 - 796.
dc.identifier.citedreferenceKozlowski AJ, Cella D, Nitsch KP, Heinemann AW. Evaluating individual change with the quality of life in neurological disorders (Neuro- QoL) short forms. Arch Phys Med Rehabil 2016; 97 ( 4 ): 650 - 654.e658.
dc.identifier.citedreferenceGoetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society- sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS- UPDRS): scale presentation and clinimetric testing results. Mov Disord 2008; 23 ( 15 ): 2129 - 2170.
dc.identifier.citedreferencePeto V, Jenkinson C, Fitzpatrick R. PDQ- 39: a review of the development, validation and application of a Parkinson’s disease quality of life questionnaire and its associated measures. J Neurol 1998; 245 ( Suppl 1 ): S10 - S14.
dc.identifier.citedreferenceIsradipine Versus Placebo in Early Parkinson Disease. A randomized trial. Ann Intern Med 2020; 172 ( 9 ): 591 - 598.
dc.identifier.citedreferenceBiglan KM, Oakes D, Lang AE, et al. A novel design of a Phase III trial of isradipine in early Parkinson disease (STEADY- PD III). Ann Clin Transl Neurol 2017; 4 ( 6 ): 360 - 368.
dc.identifier.citedreferenceHolloway RG, Dick AW. Clinical trial end points: on the road to nowhere? Neurology 2002; 58 ( 5 ): 679 - 686.
dc.identifier.citedreferenceBiglan KM, Ravina B. Neuroprotection in Parkinson’s disease: an elusive goal. Semin Neurol 2007; 27 ( 2 ): 106 - 112.
dc.identifier.citedreferenceKalia LV, Kalia SK, Lang AE. Disease- modifying strategies for Parkinson’s disease. Mov Disord 2015; 30 ( 11 ): 1442 - 1450.
dc.identifier.citedreferenceLamichhane D, Gruber- Baldini AL, Reich SG, Shulman LM. Asymmetric responsiveness of disability and health- related quality of life to improvement versus decline in Parkinson’s disease. Qual Life Res 2016; 25 ( 12 ): 3139 - 3145.
dc.identifier.citedreferenceYang J, Hanna- Pladdy B, Gruber- Baldini AL, et al. Response shift - The experience of disease progression in Parkinson disease. Parkinsonism Relat Disord 2017; 36: 52 - 56.
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
mds28641.pdf
Size:
168.1KB
Format:
PDF
View/Open
Name:
mds28641_am.pdf
Size:
5.031MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.